Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Anthropic IPO Marketing Expected to Start in Mid-October 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
AstraZeneca (LON: AZN) reported stronger-than-expected second-quarter earnings on Monday, reaffirming its 2026 guidance as robust demand for its Oncology and Rare Disease portfolio continued to offset the impact of Farxiga's U.S. patent expiry.
The British pharmaceutical company posted core earnings of $2.63 per share for the quarter ended June 30, an 18% increase from a year earlier and above analysts' consensus estimate of $2.48 per share. Revenue rose 5% at constant exchange rates to $15.38 billion, narrowly missing analyst expectations of $15.39 billion.
Investor sentiment remained positive, with AstraZeneca shares rising about 1% in London trading following the results. The company reported operating profit of $3.16 billion, pre-tax profit of $2.8 billion, and a core operating margin of 34%.
AstraZeneca maintained its full-year 2026 outlook, forecasting low double-digit growth in core earnings per shareand mid-to-high single-digit revenue growth. The company also said favorable foreign exchange rates could provide a low single-digit boost to annual revenue if current currency trends continue.
Chief Executive Pascal Soriot acknowledged the disappointing outcome of the CARDIO-TTRansform study but emphasized confidence in the company's long-term growth strategy.
"We remain on track to achieve our ambition of $80 billion in annual revenue by 2030, which factors in both clinical successes and setbacks," Soriot said. He added that AstraZeneca's development pipeline remains strong, with more than 20 major clinical readouts expected over the next 18 months.
Following the earnings release, Bank of America reiterated its Buy rating on AstraZeneca, arguing that upcoming pipeline milestones could support a higher valuation. The brokerage noted the stock trades at roughly 16 times projected 2027 earnings, while its medium-term outlook could justify a valuation closer to 18 times earnings.
The company also provided an update on Ultomiris, reporting that its Phase III trial in adult and adolescent patients with HSCT-TMA did not meet its primary endpoint. However, the pediatric study produced encouraging results, with 87.2% survival at 26 weeks and 73.4% survival at 52 weeks. AstraZeneca said it is moving forward with regulatory submissions for pediatric HSCT-TMA, noting that Ultomiris maintained a safety profile consistent with previous studies and continues to demonstrate a favorable treatment trend in adult and adolescent patients.
